has spread to other parts of the body or cannot be removed by surgery (metastatic), and
whose tumors have an abnormality in their mesenchymal-epithelial transition (MET) gene
The effectiveness of TABRECTA in these patients is based on a study that measured 2 types of response to treatment (response rate and duration of response). There is no clinical information available to show if patients treated with TABRECTA live longer or if their symptoms improve. There are ongoing studies to find out how TABRECTA works over a longer period of time.
It is not known if TABRECTA is safe and effective in children.
How does TABRECTA work?
TABRECTA works by blocking the activity of proteins made by METex14 that can cause your cancer to grow
TABRECTA affects both cancer cells and healthy cells
Although TABRECTA has been studied in people with NSCLC, how TABRECTA works has been demonstrated only in laboratory studies
You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or click OK to continue.